2023 World Conference on Lung Cancer (Posters)-EP11.03. Anti-angiogenic Therapy or Immunotherapy? A Multicenter Study of Patients with Advanced NSCLC with EGFR / HER2 exon 20 Insertion Mutations

EP11.03. Anti-angiogenic Therapy or Immunotherapy? A Multicenter Study of Patients with Advanced NSCLC with EGFR / HER2 exon 20 Insertion Mutations - PDF(Slides)

Back to course

Pdf Summary

The study analyzed patients with advanced non-small cell lung cancer (NSCLC) who had EGFR/HER2 exon 20 insertion mutations. The standard treatment for these patients is platinum-containing double-drug chemotherapy, as first-generation TKIs have limited efficacy against these mutations. The effectiveness of second- and third-generation TKIs is still uncertain, and there is a need for more treatment options.<br /><br />The study reviewed patients treated at two hospitals in Shanghai from 2015 to 2022. The researchers assessed the efficacy of various treatments, including objective response rate (ORR) and disease control rate (DCR), as well as progression-free survival (PFS) and overall survival (OS).<br /><br />In the first-line treatment, bevacizumab chemotherapy (BevaChemo) and ICIchemotherapy (ICIChemo) showed higher ORR and DCR compared to chemotherapy alone (Chemo). The median PFS was also longer with BevaChemo and ICIChemo. ICIChemo showed a trend towards improved OS.<br /><br />In a stratified analysis of first-line treatment, ICIChemo was more effective than chemotherapy for patients with EGFR 20ins mutation, with longer median PFS and a trend towards improved OS.<br /><br />For patients with HER2 20ins mutation in the first-line treatment, BevaChemo was more effective with longer median PFS compared to chemotherapy.<br /><br />In the second-line treatment for patients with EGFR 20ins mutation, bevacizumab chemotherapy showed significant advantages in PFS compared to targeted therapy.<br /><br />Overall, the study provides evidence for the efficacy of immunotherapy and bevacizumab chemotherapy in patients with EGFR/HER2 exon 20 insertion mutations. These findings offer new treatment options for this specific group of patients.

Asset Subtitle

Tianqing Chu

Meta Tag

Speaker Tianqing Chu

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

advanced non-small cell lung cancer

EGFR/HER2 exon 20 insertion mutations

platinum-containing double-drug chemotherapy

first-generation TKIs

second- and third-generation TKIs

treatment options

objective response rate

disease control rate

progression-free survival

overall survival